Macrophage-mediated response to hypoxia in disease by Tazzyman S et al.
© 2014 Tazzyman et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Hypoxia 2014:2 185–196
Hypoxia Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
185
Review
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/HP.S49717
Macrophage-mediated response to hypoxia in 
disease
Simon Tazzyman1
Craig Murdoch2
James Yeomans1
Jack Harrison1
Munitta Muthana3
1Department of Oncology, 2School 
of Clinical Dentistry, 3Department of 
infection and immunity, University of 
Sheffield, Sheffield, UK
Correspondence: Munitta Muthana 
Department of infection and immunity, 
The University of Sheffield Medical 
School, Beech Hill Road, Sheffield,  
S10 2RX, UK 
Tel +44 114 226 5852 
Fax +44 114 271 3892 
email m.muthana@sheffield.ac.uk
Abstract: Hypoxia plays a critical role in the pathobiology of various inflamed, diseased 
tissues, including malignant tumors, atherosclerotic plaques, myocardial infarcts, the synovia 
of rheumatoid arthritic joints, healing wounds, and sites of bacterial infection. These areas of 
hypoxia form when the blood supply is occluded and/or the oxygen supply is unable to keep 
pace with cell growth and/or infiltration of inflammatory cells. Macrophages are ubiquitous in 
all tissues of the body and exhibit great plasticity, allowing them to perform divergent func-
tions, including, among others, patrolling tissue, combating invading pathogens and tumor 
cells, orchestrating wound healing, and restoring homeostasis after an inflammatory response. 
The number of tissue macrophages increases markedly with the onset and progression of many 
pathological states, with many macrophages accumulating in avascular and necrotic areas, where 
they are exposed to hypoxia. Recent studies show that these highly versatile cells then respond 
rapidly to the hypoxia present by altering their expression of a wide array of genes. Here we 
review the evidence for hypoxia-driven macrophage inflammatory responses in various disease 
states, and how this influences disease progression and treatment.
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Introduction
Macrophages are extremely versatile cells that adopt a distinct phenotype in response 
to a changing microenvironment. These cells are derived from circulating monocytes 
that exit the vasculature and invade into the surrounding tissues where they differen-
tiate under the influence of local signals into resident tissue macrophages. Resident 
macrophages have a variety of roles; they patrol tissues for damaged or apoptotic cells, 
which they clear by phagocytosis, they identify and eliminate such invading pathogens 
as bacteria, fungi, and virally infected cells, they scavenge lipoproteins, and they are 
also responsible for regulating tissue oxygenation by influencing the formation of new 
blood vessels and modulating vascular permeability.1 Although tissue macrophages are 
anatomically distinct from one another, and have different transcriptional profiles and 
functional capabilities, they are all required for the maintenance of homeostasis. How-
ever, these reparative and homeostatic functions can be subverted by chronic insults, 
resulting in a causal association of macrophages with disease states. One such insult 
is hypoxia, which usually occurs due to an inefficient blood supply or where there is an 
imbalance between the number of actively respiring cells and the supply of oxygen at a 
particular localized tissue site. Of course, in such diseases as tumors, both these things occur 
simultaneously. When macrophages experience hypoxia, they respond to it rapidly with 
altered gene expression,   mediated, in part, via   upregulation of the transcription factors, Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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hypoxia-inducible factors 1 and 2 (HIF-1 and HIF-2).2,3 These 
consist of a distinct hypoxia-inducible α subunit and a com-
mon, constitutively expressed β subunit. HIF-1α and HIF-2α 
protein stability is negatively regulated by prolyl hydroxylase 
domain protein-(PHD) dependent hydroxylation, which leads 
to von Hippel–Lindau protein-(VHL) dependent ubiquitina-
tion and proteasome-dependent degradation under normoxic 
conditions.4,5 HIF-1α and HIF-2α transactivation function 
is negatively regulated by factor inhibiting HIF-1 (FIH-1) 
through FIH-1-dependent asparaginyl hydroxylation, which 
blocks binding of the coactivators, CREB-binding protein 
(CBP) and p300.6,7 Thus, the stability and activity of the 
HIFs are modulated by hydroxylation, such that changes in 
oxygen availability are transduced to the nucleus as changes 
in HIF activity (Figure 1).8
A number of studies have documented the distinct 
changes in gene expression that occur in macrophages 
when they experience hypoxia in vitro (see summary in 
Table 1). These include upregulation of molecules required 
for macrophage survival, tissue revascularization (and thus 
reoxygenation of the ischemic site), matrix remodeling, 
and recruitment and activation of more macrophages and/
or other inflammatory cells.2,8,9 Importantly, a macrophage 
in a hypoxic tumor microenvironment is likely to express 
different genes than a macrophage in a hypoxic area in a 
wound, as other stimuli besides hypoxia will be present. 
In this review, we outline the responses of macrophages to 
hypoxia in a number of inflamed and/or diseased tissues. 
We then discuss the possible implications of these for their 
progression and treatment.
Malignant tumors
One of the defining features of the tumor microenvironment 
is the presence of hypoxia. Within normal healthy tissue, 
oxygen levels are maintained within a typical range of 
20–80 mmHg, due to a balance between supply and demand. 
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Figure 1 Schematic diagram of the HiF-1α pathway.
Notes: in normoxia (A), PHDs hydroxylate specific proline residues of HIF-1α, leading to its proteosomal degradation, mediated by pvHL, an e3 ubiquitin ligase. During 
hypoxia (B), the lack of oxygen inhibits the actions of PHDs, and HiF-1α is not ubiquitinylated and then degraded. HiF-1α builds up and translocates to the nucleus where it 
binds to HiF-1β and p300. This complex then acts as a transcription factor that binds to HRes to induce expression of hypoxia-regulated genes. 
Abbreviations: UB, ubiquitin; HiF-1, hypoxia-inducible factor-1; OH, hydroxyl; vHL, von Hippel–Lindau protein; HRe, hypoxia response element; PHD, prolyl hydroxylase 
domain protein; p, phosphorylated.Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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In tumor tissues, this balance is disrupted by a combination 
of increased metabolic activity, due to rapidly dividing tumor 
cells, and a poor supply of oxygen from the poorly developed 
vasculature.10 This leads to some tumor regions experiencing 
oxygen levels below 10 mmHg or ,1.3% oxygen. Use of 
hypoxic cell markers, like pimonidazole, has demonstrated 
the presence of both transient (avascular, nonnecrotic) and 
chronic (perinecrotic) areas of hypoxia in both human and 
experimental tumors.11,12
Tumor hypoxia is thought to play an important part in 
the education of tumor-associated macrophages (TAMs). 
Indeed, analysis of these hypoxic regions revealed a large 
infiltration of TAMs than has been observed in multiple tumor 
types, including breast, endometrial, ovarian, colorectal, 
prostate, and oral tumors.13–16 The accumulation of TAMs 
in these hypoxic areas is mediated by several mechanisms, 
including active recruitment to the tumor and inhibition of 
macrophage escape (Figure 2). In response to reduced oxy-
gen tension, tumors release such hypoxia-induced chemoat-
tractants as vascular endothelial growth factor (VEGF) A, 
endothelins, endothelial monocyte-activating polypeptide-II 
(EMAPII), angiopoietin 2, and CXCL12 (stromal cell-
derived factor 1 [SDF-1]).17 For example, correlative studies 
have demonstrated that poorly vascularized areas of breast 
tumors express high levels of VEGF and have increased TAM 
numbers.18 More recently, the hypoxia-induced tumor-derived 
chemoattractant CXCL12 was shown to be the main driver 
for TAM accumulation in experimental murine gliomas, 
where it also increased their survival.19 CXCL12 binds to 
the macrophage cell surface receptor, CXCR4, which is 
upregulated through a HIF-1α-dependent mechanism in 
both monocytes and macrophages. Therefore, the hypoxia-
dependent CXCL12/CXCR4 axis is likely to be important for 
the chemotaxis of TAMs to hypoxic tumor sites.20 Similarly, 
semaphorin 3A (Sema3A) also acts as an attractant for TAMs, 
by triggering VEGF-1 phosphorylation through the Neuro-
pilin-1 (Nrp1) and PlexinA1/PlexinA4 receptors.21 When 
Nrp1 levels are downregulated in the hypoxic environment, 
Sema3A continues to regulate TAMs in an Nrp1-independent 
manner, by eliciting PlexinA1/PlexinA4-mediated stop sig-
nals, which retain TAM inside the hypoxic niche. Interest-
ingly, in a mouse model, where macrophages had a genetic 
deletion of Nrp1, it was shown that TAMs were retained in 
normoxic tumor sites, and this resulted in the prevention of 
tumor growth and metastasis.21
Since macrophages are phagocytes, they may also 
be attracted to hypoxic, perinecrotic areas via the trail of 
necrotic debris emanating from dead cells. Necrotic cells 
release high-mobility group box 1 (HMGB1) at sites of 
chronic tumor hypoxia, that has been shown to alter the 
phenotype of macrophages,22 although it has yet to be shown 
that tumor-derived necrotic debris can mediate monocyte 
recruitment to tumors. Once monocytes/macrophages are 
recruited, the presence of hypoxia has also been implicated 
in their retention in these areas. Hypoxic macrophages 
Table 1   Summary  of  select  cytokines/proteases  regulated  by 
hypoxic macrophages 
Gene Functions Up- or  
downregulated
Glut-1 Survival Up
VEGF Angiogenesis Up
TNF-α Inflammation, angiogenesis,  
apoptosis
Up
MIF Multiple effects on  
inflammation including  
immobilizing macrophages
Up
IL-1α Inflammation and  
angiogenesis
Up
IL-1β Proinflammatory,  
angiogenesis
Up
IL-8  
(CXCL8)
Proangiogenic  
and chemoattractant  
for neutrophils
Up
ANGPT2 Angiogenesis and  
chemotactic for  
Tie2-positive monocytes
Up
MMP7 wound healing,  
angiogenesis, metastasis
Up
TIMP1 inhibits activity of most  
known MMPs. Stimulates  
proliferation in a wide range  
of cell types
Up
GRO-α and GRO-β  
(CXCL1 and CXCL2)
Chemotactic for neutrophils Up
Rantes  
(CCL5)
Chemotactic for T-cells,  
eosinophils, and basophils;  
recruits leukocytes to  
inflammatory sites
Up
CSF2  
(GM-CSF)
Stimulates stem cells in the  
bone marrow to produce  
granulocytes and monocytes
Up
TNFSF13B Cell proliferation Down
ORP150 Proatherosclerotic Up
CCL2 Chemotactic for monocytes Down#
Notes:  #Upregulated indirectly by hypoxia in atherosclerosis. This research was 
originally published in Blood. Adapted from: Fang HY, Hughes R, Murdoch C, et al. 
Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary 
macrophages experiencing hypoxia. Blood. 2009;114(4):844–859. © by the American 
Society of Hematology.2
Abbreviations: Glut-1, glucose transporter-1; veGF, vascular endothelial growth 
factor; TNF, tumor necrosis factor; MiF, macrophage inhibitory factor; iL, interleukin; 
ANGPT2, endothelial Tie2/Tek ligands angiopoietin-1; MMP, matrix metalloproteinase; 
TiMP, tissue inhibitor of metalloproteinase-1; GRO, growth-regulated oncogene; CSF, 
colony-stimulating  factor;  GM-CSF,  granulocyte-macrophage  colony-stimulating 
factor; TNFSF, tumor necrosis factor (ligand) superfamily; ORP, oxygen-regulated 
protein; CCL, chemokine (C-C motif) ligand.Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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Figure 2 Schematic representation of the role of macrophages following exposure to hypoxia in varying disease states.
Notes: Macrophages are recruited as monocytes from circulation. They enter the hypoxic environment of the diseased tissue and upregulate cytokines/proteases (black 
arrows) that mediate downstream biological functions (gray boxes) in each disease state. The up arrows correspond to an increase in expression or activity; the down arrows 
correspond to a downregulation in expression or activity.
Abbreviations: veGF, vascular endothelial growth factor; MMP, matrix metalloproteinase; PGe2, prostaglandin e2; HGF, hepatocyte growth factor; iL10, interleukin 10; 
ORP150, oxygen-regulated protein 150; ROS, reactive oxygen species; TNF-α, tumor necrosis factor alpha; iL-1β, interleukin 1 beta; vLDLR, very low-density lipoprotein 
receptor; CCL2, chemokine (C-C motif) ligand 2; HiF-1, hypoxia-inducible factor-1; Mϕ, macrophage; ORP150, oxygen-regulated protein 150; RA, rheumatoid arthritis.
upregulate   mitogen-activated protein kinase phosphatase 
(MKP-1)23 that, in turn, dephosphorylates the signaling 
enzymes MEK, ERK1/2, and p38 MAPK. This effectively 
prevents macrophages from responding to a multitude of 
chemotactic factors, including VEGF and chemokine (C-C 
motif) ligand (CCL) 2, that function through this signaling 
mechanism.24 Additionally, hypoxia reduces the expression of 
the chemokine receptors CCR2 and CCR5, further preventing 
macrophages from responding to chemotactic signals outside 
the hypoxic environment.25,26
Once within the hypoxic tumor microenvironment, mac-
rophages are induced to undergo a phenotype change toward 
what has been termed an M2, or alternatively activated 
state.27 Exposure to hypoxia induces the build-up of the 
transcription factors HIF-1α and HIF-2α. These transcrip-
tion factors bind to hypoxia response elements in a number 
of genes, increasing their transcription. Notably, in response 
to hypoxia, macrophages have been shown to induce such 
proangiogenic molecules as VEGF, fibroblast growth factor-
(FGF) 2, CXCL8, cyclooxygenase-2, hepatocyte growth 
factor (HGF), and matrix   metalloproteinase- (MMP) 12.2,18 
There is now emerging data to show that tumor hypoxia also 
establishes an immunosuppressive macrophage   phenotype. 
The expression of such immunosuppressive factors as 
prostaglandin E2 (PGE2)28 and interleukin (IL) 1029 are 
increased in hypoxia, and their presence within the tumor 
microenvironment can downregulate the tumoricidal abili-
ties of TAMs. In addition, PGE2 and IL-10 inhibit the func-
tions of cytotoxic CD8+ T lymphocytes and other effector 
cells of the immune system,30 which, combined with hypoxic 
inhibition of macrophage phagocytosis and antigen presen-
tation, suppresses the triggering of an adaptive immune 
response toward tumor cells. Moreover, Doedens et al 
recently reported hypoxia- and HIF-1-dependent in vitro 
suppression of T-cell proliferation by macrophages.31
The hypoxia-induced skewing of macrophages toward an 
M2 state may not be entirely under the control of HIF-1α. 
Interestingly, Werno et al demonstrated that HIF-1α-deficient 
macrophages exposed to hypoxia were more M2-polarized, as 
assessed by their lower cytotoxicity toward tumor cells and the 
lack of a response to lipopolysaccharide (LPS) stimulation. In 
addition, the proangiogenic functions of these macrophages 
were decreased, compared to wild-type macrophages.32 
Taken together, these data show a clear role for hypoxia in Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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the   promotion of tumors, by encouraging   macrophages to 
support many aspects of tumor development.
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic systemic autoim-
mune disease characterized by a symmetrical, inflammatory 
arthropathy that results in destruction of bone and cartilage, 
leading to joint stiffness, significant pain, and loss of func-
tional capacity.33 Although the pathogenesis of RA is still 
not completely understood and treatment is non-curative, 
studies suggest that genetic and environmental factors can 
trigger joint inflammation.34–36
An early event in inflammatory arthritic joints is hypoxia-
driven angiogenesis, where new blood vessels invade the 
synovial tissue, resulting in persistent infiltration of leuko-
cytes into the synovial fluid and the dramatically increased 
proliferation of synovial fibroblasts.33 Although these new 
blood vessels deliver oxygen to the inflammatory cell mass, 
the vascular network is dysfunctional, so the synovium 
remains a markedly hypoxic environment.37 Hypoxia and 
angiogenesis are now recognized as seminal events in the 
perpetuation of joint destruction in RA.38–41
The presence of hypoxia in the human RA joint was 
initially confirmed using microelectrodes that measured oxy-
gen tension indirectly in the synovial fluid.42,43 More recent 
studies using a combined oxygen and temperature probe in 
patients with inflammatory arthritis showed that low synovial 
pO2 levels (,20 mmHg) significantly correlated with joint 
inflammation,44 lipid peroxidation, secretion of angiogenic 
factors, and the presence of T-cells and macrophages in the 
sublining layer of the synovium.45 Animal models of RA also 
display pO2 levels as low as 10 mmHg, and extensive hypoxia 
has been shown in the synovium, pannus, bone marrow, and 
articular cartilage chondrocytes in the arthritic joints of rats 
in in vivo models of the disease.38,46 Repetitive cycles of 
hypoxia and reoxygenation, together with oxidants produced 
by macrophages and neutrophils, lead to the production of 
reactive oxygen species that result in significant tissue dam-
age in RA joints.47,48 Hypoxia also aggravates the synovial 
inflammatory lesion by increasing local production of such 
enzymes as COX-2 and MMPs by synoviocytes, monocytes/
macrophages,49 and fibroblast-like synoviocytes.50,51 COX-2 
catalyzes the conversion of arachidonic acid, which is cleaved 
from membrane phospholipids, to form proinflammatory 
eicosanoids such as PGE2 and prostacyclin I2 (PGI2). COX-2 
expression is highly elevated in the RA synovium and has 
a direct relation to the degree of inflammation in synovial 
tissue.52 PGE2 is involved in the erosion of cartilage and 
juxta-articular bone,53 stimulates the production of MMPs,54 
and contributes to angiogenesis,55 all of which are important 
mediators of connective tissue degradation in the synovium.
A large proportion of macrophages have been shown to 
accumulate in the RA synovium, with most residing in the 
inflamed lining layer. In fact, Hollander et al reported that 
.90% of the cells in the RA synovial lining stained positive 
for the pan-macrophage marker CD68.56 Immunohistochemi-
cal studies have revealed that both HIF-1α and HIF-2α are 
overexpressed in the synovial lining of patients with RA, 
compared to healthy joints.57 Importantly, Hollander et al 
found that the CD68+ cells in RA joints also expressed 
HIF-1α and were not detected in the synovium of normal or 
osteoarthritic (nonhypoxic) joints,56 suggesting that hypoxic, 
HIF-1α-activated macrophages are overrepresented in RA 
joints. In addition, Cramer et al showed that when arthritis 
was induced in the joints of mice bearing a targeted deletion 
of the HIF-1α gene in myeloid cells (macrophages and neutro-
phils), the mice displayed a marked reduction in joint swelling 
and reduced synovial infiltration by macrophages, strongly 
implicating the hypoxic-induced responses of these cells in 
RA pathology.58 A number of known hypoxia-regulated genes/
proteins are also known to be expressed by macrophages in 
RA joints, including CXCL12,59 CXCL8,60 VEGF,61 IL-1β, 
and tumor necrosis factor-(TNF) α,62 which potentiate the 
inflammatory response and stimulate angiogenesis in RA. 
IL-1β and TNF-α are essential proinflammatory cytokines 
required for the progression of RA, because they are capable 
of inducing other proinflammatory cytokines and activating 
MMPs in autocrine and paracrine fashions.63 Inhibitors of 
IL-1 and TNF-α cause a reduction in synovial inflammation, 
bone destruction, and macrophage infiltration in patients 
with RA.64,65 A critical role of TNF-α and IL-1 during RA 
pathogenesis was confirmed by the recent development of 
new drugs targeting these molecules, that has revolutionized 
patient treatment.66
These data provide clear evidence that activation of 
HIF-1α in macrophages and the subsequent expression of 
HIF-1α target genes in these cells is an important contributor 
to the pathogenesis of RA. Whether HIF-1α alone is suf-
ficient to drive RA has not been demonstrated. HIF-2α, a 
protein closely related to HIF-1α, is also expressed in the 
RA synovium.57 However, to date, there is little information 
on the role of HIF-2α-expressing macrophages in hypoxic 
joints of RA patients.
Precisely how hypoxia regulates the activity HIF-1α and 
HIF-2α transcription factors in the RA joint has yet to be 
determined. In view of the abundance of macrophages in the Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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synovia of RA joints, and their increased activity of HIFs and 
subsequent expression of various proinflammatory   HIF-target 
genes, it would be interesting to see whether inflammation in 
RA joints would be dampened by suppressing the   expression/
function of macrophage HIF-1α or HIF-2α. This could be 
achieved by injecting the synovial fluid of RA joints with 
a vector that bears short hairpin RNA (shRNA) for HIFs. 
More recently, highly selective antagonists have been devel-
oped that suppress HIF-1α and HIF-2α in vitro and in vivo, 
reducing the expression of HIF-related gene targets in tumor 
cells67,68 and inhibiting tumor angiogenesis;66,69 so, these could 
also be applied to RA. Such chemical tools provide a potential 
therapeutic opportunity to intervene in HIF-driven RA.
Atherosclerosis
Atherogenesis is most commonly thought to occur at sites 
of vessel wall injury, where it is heralded by endothelial cell 
dysfunction. This results in lipid accumulation and inflam-
matory cell infiltration, including monocyte recruitment into 
the arterial intima.70 These monocytes differentiate into mac-
rophages that ingest such lipoproteins as oxidized low-density 
lipoprotein (LDL) and native LDL, resulting in cells laden 
with cytoplasmic lipid vacuoles, that are often termed “foam” 
cells.71 Accumulating “foam” cells form the fatty streak 
characteristic of early atherosclerosis and remain present in 
the mature atherosclerotic plaque.72 As the plaque develops, 
the arterial wall increases in volume, resulting in reduced 
oxygen diffusion and subsequent hypoxia.   Bjornheden et al 
demonstrated arterial hypoxia at distances of 200–300 µm 
from the endothelial surface of atherosclerotic plaques in 
rabbits, and observed large numbers of “foam” cells within 
these regions, indicating these macrophages experience 
hypoxia in atherosclerosis.73
Hypoxia significantly contributes to lipid metabolism in 
human macrophages in vitro. Bostrom et al demonstrated that 
human macrophages were capable of increasing triglyceride 
content in response to hypoxia, while Parathath et al observed 
an increase in cholesterol content within macrophages.74,75 
In vitro, hypoxia upregulates macrophage expression of 
15-lipooxygenase-2 leading to increased LDL oxidation.76 
15-lipooxygenase-2 expression also lead to increased 
expression of CXCL10 and CCL2, resulting in the increased 
T-cell recruitment observed in atherosclerosis.77 Very low-
density lipoprotein (VLDL) receptors are upregulated on 
macrophages experiencing hypoxia, and are also known to 
be upregulated on plaque macrophages in vivo,78 suggest-
ing a correlation between hypoxia and plaque macrophage 
expression of VLDL receptors. The VLDL receptor mediates 
the uptake of such lipids as β-VLDL, chylomicron remnant, 
and lipoprotein Lp(α), suggesting hypoxia also affects lipid 
metabolism through VLDL receptor-derived pathways.78–80
T lymphocyte recruitment, along with endothelial cell 
and smooth muscle migration and proliferation, is vital for 
the progression of atherosclerosis. CXCL8 is chemotactic 
for T lymphocytes,81 and both chemotactic and mitogenic 
for endothelial82 and smooth muscle cells.83 Human foam 
cells taken from atherosclerotic plaques release increased 
levels of CXCL8, compared to cultured monocytes and 
macrophages,84 while CXCR2-deficient mice demonstrated 
reduced atherosclerosis compared to wild-type mice.85 
These findings suggest CXCL8 aids atherosclerotic plaque 
development. Hypoxia itself has been shown to upregulate 
macrophage CXCL8 gene expression and foam cell produc-
tion of CXCL8,86,87 suggesting hypoxia prompts increased 
CXCL8 secretion from foam cells, leading to atherosclerotic 
development via interactions with T lymphocytes, endothelial 
cells, and smooth muscle.
Foam cells secrete a wide variety of other proteins in 
response to hypoxia. Foam cells from human atheroscle-
rotic lesions have shown oxygen-regulated protein (ORP) 
150 expression in response to hypoxia and the presence of 
oxidized LDL.88 ORP150 expression by macrophages has 
been linked to subsequent increased VEGF expression and 
angiogenesis,67 and it has been suggested that ORP150 plays 
an important role in preventing hypoxia-induced apoptotic 
cell death.90 This, combined with its expression in areas of 
high oxidized LDL concentration, suggests that this factor 
has a protective role against environmental stressors in the 
atherosclerotic milieu. Macrophage inhibitory factor (MIF) 
is a protein that is highly expressed by human foam cells, 
and its expression is strongly correlated to neovascularization 
and other signs of atherosclerotic plaque instability.91 Burger-
Kentischer et al found treatment with a MIF antibody in an 
atherosclerotic-prone murine model resulted in reduction of 
a number of inflammatory markers typically associated with 
atherosclerosis, suggesting that MIF had a mediating effect on 
intimal inflammation.92 In addition, MIF blockade in murine 
models has resulted in plaque regression and reduced levels 
of T lymphocytes and macrophages.93 In addition, VEGF has 
been shown to be expressed in significantly greater amounts in 
hypoxic foam cells than nonhypoxic foam cells in vivo.75 Other 
factors known to be induced by hypoxia are also expressed by 
foam cells, such as platelet-derived growth factor (PDGF),94 
TNF-α, IL-1,95 CCL2,96 MMP-1,97 MMP-7,98 though it is not 
yet directly known if foam cells vary their expression of these 
factor in a hypoxia-dependent manner.Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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One of the complications of atherosclerosis is myocardial 
infarction (MI), which results from plaque rupture, creating 
microemboli that can occlude blood vessels.99 If this occurs 
in coronary arteries, it can cause chronic hypoxia in the 
  myocardium. Regions of myocardial hypoxia have been dem-
onstrated in canine models of MI, and macrophages have been 
found in significantly greater quantities in human myocardium 
from ischemic heart disease patients than in controls.100,101 
Macrophages recruited to the damaged tissue may be ben-
eficial in heart recovery. Researchers have demonstrated that, 
after MI, these recruited macrophages express high levels of 
PR-39 (originally identified as an antibacterial peptide).102 
This research group went on to demonstrate that PR-39 had 
a proangiogenic effect on mice myocardium via inhibition 
of HIF-1α degradation, resulting in increased HIF-1α levels 
and, consequently, growth factor expression.103 Evidence that 
elevated levels of PR-39 may be beneficial in MI has been 
shown with the use of recombinant adeno-  associated virus, 
engineered to overexpress this gene. Use of this virus in a 
porcine model of MI resulted in decreased infarct areas in 
MI, creating the tantalizing possibility of utilizing PR-39 as 
a potential therapeutic agent in the future.104
Wound healing
Ischemia is a common event in wounds that often leads to 
local tissue hypoxia. Wounds compromising the epidermis 
and entering the underlying connective tissue disrupt the local 
vasculature, leading to localized bleeding, blood vessel vaso-
constriction, and clot formation. Hypoxia within the wound 
can then develop, due to both a reduction in local perfusion 
and increased oxygen demand of the cells within the healing 
tissue.105 Oxygen tension measurements in rodent models 
decreased from 150 mmHg to 20–30 mmHg immediately 
after injury and, in some instances, these oxygen tensions 
decreased further to 5–7 mmHg 3–5 days post-injury.106 This 
acute hypoxia is thought to be essential for tissue repair, by 
activating platelet aggregation and promoting release of such 
growth factors and cytokines as VEGF and TNF-α.107–109 In 
addition to the typical laceration wound, hypoxia is also 
observed in burn wounds. Xing et al studied the expression 
of HIF-1α along with the hypoxic marker pimonidazole, in 
order to examine the spatial and temporal course of hypoxia 
in a murine burn model. They found that the leading edge of 
the healing burn was hypoxic and that this level of hypoxia 
correlated positively with increased expression of HIF-1α, as 
well as the proangiogenic factors VEGF and CXCL12.108
Inflammatory cell infiltration of wounds has long been 
accepted. Neutrophils are the first cells to be recruited to 
wound sites, and these are followed by infiltration of mono-
cytes that quickly differentiate into macrophages. Later, 
lymphocytes enter the wounds and, eventually, inflammatory 
resolution and matrix remodeling occurs.110 The importance 
of macrophages in wound healing was clearly demonstrated 
by macrophage depletion studies. Wounded transgenic mice 
devoid of macrophages showed an increased expression of 
TNF-α but decreased levels of VEGF and tumor growth 
factor (TGF)-β at the injured site. Interestingly, the altered 
expressions of these molecules were associated with a 
reduced rate of reepithelialization, impaired collagen depo-
sition, angiogenesis, and decreased cell proliferation, sug-
gesting that macrophages are important for wound closure 
and healing.111 Furthermore, application of macrophages 
into experimentally induced cutaneous wounds was shown 
to accelerate wound repair.112 Although a clear role for 
hypoxia and macrophages in wound healing is evident, the 
precise role of hypoxia-induced macrophages in this pro-
cess is less understood. Macrophages at the site of tissue 
injury have been shown to upregulate and express many 
factors that are typically secreted by hypoxic macrophages, 
including VEGF,113 PDGF,114 MMP-1,115 TNF-α, IL-1,116 
and FGF-2.117 More specifically, the increased expression of 
these molecules in hypoxic macrophages is a direct result of 
HIF-1α and HIF-2α activation.2 The importance of hypoxic 
macrophages in wounds has been suggested by Ozawa et al, 
who, using immunohistochemical staining of human wound 
granular tissue, found that CD68-positive macrophages 
coexpressed the proangiogenic factors VEGF and ORP150 
at these sites. Overexpression of ORP150 by macrophages 
in a murine wound model increased the expression of VEGF 
by these cells, that accelerated neovascularization and wound 
healing.90 Additional in vitro experiments using cultured 
macrophages under hypoxic and normoxic conditions have 
revealed a mechanism for the coexpression of these two fac-
tors. ORP150 is an endoplasmic reticulum chaperone that is 
encoded by a hypoxia-responsive gene. In hypoxic cultures, 
increased expression of ORP150 promoted secretion of 
VEGF by macrophages, while its inhibition caused retention 
of VEGF within the endoplasmic reticulum, thereby reducing 
the secretion of this angiogenic growth factor. This suggests 
that hypoxia-induced expression of ORP150 is important 
for the secretion of VEGF by hypoxic macrophages within 
healing wounds.90 Similarly, in burn wounds, macrophages 
have been found in the deep, hypoxic regions of the injury, 
where they express VEGF.109
Taken together, these data suggest that macrophages 
experiencing hypoxia within wounds drive a   proangiogenic Hypoxia 2014:2 submit your manuscript | www.dovepress.com
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  phenotype, with the expression of VEGF and other 
  proangiogenic factors to revascularize the wound site. How-
ever, there are still a limited number of publications that have 
examined the presence of macrophages in hypoxic wound 
areas, and, more importantly, the effect that hypoxia-driven 
macrophage gene products have on would healing remains 
speculative. Indeed, contradicting data regarding the role 
of hypoxic macrophages following tissue injury have been 
published. Owings et al showed that HIF-1α expression in 
myeloid cells infiltrating wounds mediated a slower rate of 
wound repair. In their experiments, myeloid-specific HIF-1α 
knockout mice showed a more rapid rate of wound closure 
when compared to wild-type controls, and this was not 
related to an alteration in angiogenesis, cell proliferation, or 
the number of recruited neutrophils or macrophages at the 
wound site.118
Bacterial infection
Hypoxia is also a feature of tissues experiencing bacterial 
infection.119 This hypoxic state is due to increased oxygen 
consumption by the proliferation of bacteria, the accumulation 
of phagocytes at the infected site, and/or the vasoconstriction 
of vessels in the area, which could impede delivery of oxygen 
to the site of inflammation. Therefore, macrophages are likely 
to experience hypoxia at sites of bacterial infection. However, 
there is currently little in vivo evidence that this directly alters/
regulates macrophage antibacterial functions. Johnson’s group 
used transgenic mice with a targeted HIF-1α knockout in 
myeloid cells to demonstrate the importance of HIF-1α in the 
antibacterial functions of macrophages, in vitro and in vivo, 
under both normoxic and hypoxic conditions.58 It has been 
shown in vitro that macrophage behavior is altered by hypoxia 
in bacterial infections. Anand et al observed an increase in 
phagocytosis of Escherichia coli by murine macrophages 
in a p38- and HIF-1α-dependent manner.120 Curiously, a 
contradictory observation has also been made; Shirato et al 
found hypoxia resulted in HIF-1α expression that was cor-
related with macrophage scavenger receptor 1 suppression 
and subsequent reduced phagocytic capacity on exposure to 
Listeria monocytogenes.121 Hypoxia has also been observed 
changing the expression of factors by macrophages during 
bacterial infection. Nickel et al observed expression of human 
β defensin 2 and upregulation of the vitamin D-dependent 
antimicrobial pathway, exclusively in response to hypoxia in 
Mycobacterium tuberculosis infections. This, in turn, resulted 
in decreased intracellular growth of M. tuberculosis.122
It should be noted that HIF-1α levels can be upregu-
lated by rat and mouse macrophage cell lines in the 
absence of hypoxia by LPS (which is present in bacterial 
cell walls).123,124 Furthermore, mouse macrophages rapidly 
upregulate their expression of HIF-1α when exposed to 
Gram-positive or Gram-negative bacteria.124 Together, these 
findings indicate that HIF-1-mediated mechanisms play an 
important part in macrophage responses to bacterial infec-
tions and that these do not necessarily require activation 
by hypoxia.
Conclusion
It is clear from the evidence cited above that macrophages 
accumulate in areas of severe hypoxia in various inflamed 
sites, where they respond to microenvironmental cues and 
contribute to hypoxia by consuming oxygen themselves. 
This raises the question of whether it might be possible to 
exploit our knowledge of how macrophages are recruited/
trapped in these hypoxic/necrotic areas, to develop new 
treatment strategies devised at targeting these pathways. 
One such treatment may also be able to exploit the natural 
propensity of macrophages to home to hypoxic areas. We 
previously described how macrophages could be isolated 
from patients, treated ex vivo to carry hypoxically-activated 
therapeutic agents, and then reintroduced back into the body, 
systemically.15 In addition, we recently demonstrated that 
the administration of macrophages “armed” with oncolytic 
virus 48 hours after treatment with the chemotherapeutic 
agent docetaxel, or following tumor irradiation, abolished 
the subsequent post-therapy regrowth of primary prostate 
tumors in mice.125 Alternatively, new therapies involv-
ing the use of peptides or small molecule antagonists to 
inhibit macrophage receptors for specific chemoattractants 
produced by hypoxic areas of tumors may help to reduce 
macrophage accumulation in these sites, while leaving 
macrophage functions in healthy tissues unaffected. This 
would then remove their proangiogenic contribution under 
hypoxia and reduce the net proangiogenic activity of cells 
in such areas.
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